Stacytine 600

Stacytine 600 reduces the viscosity of purulent and non purulent pulmonary secretions. Acetylcysteine may also protect the liver in case of overdose of paracetamol.

Pack size Box of 01 tube of 10 tablets. Box of 16 tablets (4 strips x 4 tablets)
Shelf-life 24 months
Composition Acetylcysteine
Dosage forms and strengths Effervescent tablet: 600 mg
Product code :



  • Acetylcysteine is used as a mucolytic agent in the adjunctive treatment of patients with abnormal, viscid, or inspissated mucous secretions in such conditions as acute and chronic bronchopulmonary disorders.
  • Acetylcysteine is used as an antidote for the treatment of paracetamol overdosage.


Mucolytic uses

  • Children aged 2 to 6 years old: 200 mg twice daily.
  • Adults: 200 mg three times daily or 600 mg once daily.

Antidote for paracetamol overdosage

  • Initial dose of 140 mg/kg followed by 70 mg/kg every 4 hours for an additional 17 doses.
  • Acetylcysteine is reported to be most effective when given within 8 hours of paracetamol overdosage.


Stacytine 600 is administered orally by dissolving the effervescent tablet in water.

  • Known hypersensitivity to acetylcysteine or to any ingredient in the formula.
  • Patients with asthma or a history of bronchospasm.
  • Children aged under 2 years old.
  • Hypersensitivity:
    Bronchospasm, angioedema, rashes and pruritus; hypotension, or occasionally hypertension, may occur.
  • Other adverse effects:
    Flushing, nausea and vomiting, fever, syncope, sweating, arthralgia, blurred vision, disturbances of liver function, acidosis, convulsions, and cardiac or respiratory arrest.
  • Since oral administration of acetylcysteine may result in vomiting or aggravate vomiting associated with paracetamol overdosage, patients at risk of gastric hemorrhage should be evaluated with regard to the relative risks of upper GI hemorrhage and paracetamol-induced hepatotoxicity and treatment with acetylcysteine given accordingly.
  • Asthmatic patients receiving acetylcysteine should be observed closely during such therapy; if bronchospasm occurs, a bronchodilator should be given by nebulization. If bronchospasm progresses, acetylcysteine should be discontinued immediately.
  • An increased volume of liquefied bronchial secretions may develop after administration of acetylcysteine. If cough is inadequate to maintain an open airway during acetylcysteine therapy, mechanical suction or endotracheal aspiration should be instituted.
  • Stacytine 600 contains aspartame. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly. Stacytine 600 contains sorbitol. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product.
  • Stacytine 600 can be used in pregnant and nursing women.
  • There are no known effects on ability to drive and use machines.